AstraZeneca: Airsupra U.S. Prescribing Information Updated to Reflect the Statistically Significant Severe Exacerbation Risk Reduction in Patients With Mild Asthma Compared With Albuterol
September 19, 2025
September 19, 2025
WILMINGTON, Delaware, Sept. 19 (TNSjou) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
AIRSUPRA (albuterol/budesonide) US prescribing information updated to reflect the statistically significant severe exacerbation risk reduction in patients with mild asthma compared with albuterol
The US Food and Drug Administration (FDA) has approved a supplemental
new drug application (sNDA) for AIRSUPRA
* . . .
* * *
AIRSUPRA (albuterol/budesonide) US prescribing information updated to reflect the statistically significant severe exacerbation risk reduction in patients with mild asthma compared with albuterol
The US Food and Drug Administration (FDA) has approved a supplemental
new drug application (sNDA) for AIRSUPRA
* . . .